Role of PI3K/Akt/GSK-3 Pathway in Emesis and Potential New Antiemetics
- PMID: 33426544
- PMCID: PMC7793561
- DOI: 10.33696/Signaling.1.024
Role of PI3K/Akt/GSK-3 Pathway in Emesis and Potential New Antiemetics
Keywords: Akt; Ca2+; Chemotherapy; Emesis; Emetic nuclei; GSK-3; PI3K.
Conflict of interest statement
Conflicts of Interest We have no conflict of interest to declare.
References
-
- Adel N Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. The American Journal of Managed Care. 2017. September;23(14 Suppl):S259. - PubMed
-
- Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. New England Journal of Medicine. 2016. April 7;374(14):1356–67. - PubMed
-
- Hesketh PJ. Chemotherapy-induced nausea and vomiting. New England Journal of Medicine. 2008. June 5;358(23):2482–94. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous